Physician profile
Charanjeev K Mann
NPI 1538110481
$2,766.65
in general payments reported to CMS, 2019-2025
21 companies · $983 in 2025
The $983 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $814 · 2024: $969 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,766.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $300.35 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $299.46 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $294.06 | 2023-2025 | |
| Glaxosmithkline, LLC. | $242.66 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $194.17 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $183.51 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $164.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $160.22 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $151.95 | 2023-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.00 | 2023-2024 | Caplyta |
| Exact Sciences Corporation | $138.91 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $132.05 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $122.94 | 2024 | Inspire |
| Abbott Laboratories | $48.76 | 2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $46.60 | 2023 | Injectafer |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.86 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $35.39 | 2024 | Gemtesa |
| Horizon Therapeutics Plc | $23.31 | 2023 | Krystexxa |
| Esperion Therapeutics, INC. | $16.27 | 2025 | Nexletol |
| Sanofi Pasteur INC. | $16.12 | 2025 | |
| Merck Sharp & Dohme LLC | $13.42 | 2023 | Belsomra, Steglatro, Steglujan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charanjeev Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.